Sentiss is a niche pharmaceutical company creating value globally for all its stakeholders through generic and innovative eye care and speciality products. Sentiss’ capabilities include a state-of-the-art R&D centre in India, two sterile manufacturing facilities in India and Switzerland, and a cohesive and capable team of over 1200 employees and partners enabling excellence in end-to-end operations spread across India, USA, Europe, Dubai, Russia & Central Asia. Founded in 1990, it has grown to become the largest Ophthalmic company in Russia. With the acquisition of Akorn AG, Switzerland, Sentiss has added to its capabilities a state of the art US FDA approved sterile manufacturing facility producing ophthalmic eye drops & ointments. Sentiss continues to embrace mutually rewarding strategic partnerships in the areas of contract manufacturing, in-licensing & out-licensing in markets around the world. Sentiss takes immense pride in being receiving the award for the Best use in CSR Practices in Pharmaceuticals for the 4th year in a row, and being recognised as a Great Place to Work Certified® organisation for the 8th year in a row.